Anuh Pharma dividend, bonus: FY25 results and dates

Stock snapshot and why investors tracked it

Anuh Pharma Ltd. was trading at Rs 76.64 as of 09 Jan, 2026 at 03:59 PM IST, according to the provided market data. The share price was reported to be down 1.19% from its previous close of Rs 77.56. The dataset also shows dividend yield figures in the range of 1.63% to 1.96% across different sections, alongside a stated book value per share of Rs 67.00 and face value of Rs 5.00.

The focus for investors in this period was not a single price move, but a cluster of corporate actions and disclosures. These included a 1:1 bonus issue, a final dividend timetable linked to FY2024-25, and subsequent board-level governance updates in early February 2026. The filings also provide quarterly and annual financial numbers that help contextualise the dividend decision.

FY2024-25 dividend recommendation and payout details

For FY2024-25, the company’s directors recommended a final dividend of Rs 1.50 per equity share, described as a 30% payout on the face value of Rs 5 per share, on the post-bonus share capital. The corporate action table in the text lists the dividend announcement date as 23 May 2025, with an ex-date of 14 Aug 2025 and record date of 15 Aug 2025, marked as “Final”.

The annual report excerpt in the provided text also states that the total dividend outgo shall be Rs 1,503 lakhs (Rs 15.03 crore), compared with Rs 1,253 lakhs (Rs 12.53 crore) during the previous year. Another section references a prior-year final dividend of Rs 2.50 per share (50%) versus Rs 2.00 per share (40%) for the previous year in that context, but the FY2024-25 dividend repeatedly appears as Rs 1.50 per share in the corporate action and AGM-related extracts.

Bonus issue and key corporate action dates

The corporate action section lists a bonus issue in the ratio of 1:1, with an ex-date of 15 Jul 2025. Separately, the dividend ex-date is shown as 14 Aug 2025 for “Dividend - Rs 1.50 Per Share”. These dates matter for eligibility, because the record date determines which shareholders receive the benefit.

The BSE announcement excerpt dated 29/07/2025 notes that the record date was revised and fixed as Friday, 15th August, 2025, for determining eligibility for the final dividend for FY2024-2025, if declared and approved by members at the AGM. The same note also links the record date to voting eligibility through remote e-voting or at the AGM.

AGM outcome and approvals listed in the text

The provided text states that Anuh Pharma’s Board approved audited financial results for the year ending March 31, 2025, including the 1:1 bonus equity share issue and a proposed dividend of Rs 1.50 per share, subject to shareholder approval. It also mentions that the draft notice for the Annual General Meeting was approved, with the AGM scheduled for August 22, 2025.

Another excerpt summarises the AGM outcome as declaring the Rs 1.50 per share dividend, and recording re-appointments of directors. The same section indicates joint managing directors were reappointed for a five-year term from 08 Jan 2026 to 07 Jan 2031.

Quarterly performance: income, profit, and EPS

The “Financial Results (Amount in Lakhs.)” table provides quarterly snapshots. Converting the stated lakh figures into crore for consistency, the company reported total income of Rs 189.87 crore for the quarter ended 30-Jun-2025, with net profit of Rs 8.30 crore and EPS of 1.66. For the quarter ended 31-Mar-2025, total income was Rs 199.54 crore, net profit Rs 12.46 crore, and EPS 2.49.

For the quarter ended 31-Dec-2024, total income was Rs 160.45 crore, net profit Rs 10.34 crore, and EPS 2.06. Separately, the disclosure on 6 Feb (year shown as 2026 in the text) states Q3 FY26 revenue of Rs 197.18 crore and PAT of Rs 13.45 crore, and 9M PAT of Rs 29.36 crore.

FY2024-25 annual performance and profitability trend

The annual report extract states revenue from operations for the year ended 31 March, 2025 amounted to Rs 66,151 lakhs, which is Rs 661.51 crore. It compares this with Rs 64,700 lakhs, or Rs 647.00 crore, for the previous year, describing the increase as about 2%.

On profitability, the same extract says profit before tax reduced by 22% from Rs 7,831 lakhs (Rs 78.31 crore) to Rs 6,100 lakhs (Rs 61.00 crore). Profit after tax reduced by 21% from Rs 6,006 lakhs (Rs 60.06 crore) to Rs 4,735 lakhs (Rs 47.35 crore). A separate multi-year metrics table in the text also shows revenue at Rs 661.51 crore and net profit at Rs 47.35 crore for the latest year in that series.

Balance sheet and reserves: assets and planned transfers

A board-related excerpt in the text states total assets as of March 31, 2025 were Rs 50,662.77 lakhs, which is Rs 506.63 crore, and describes this as significant growth from the previous year (without specifying the prior-year number in that line). The annual report excerpt also mentions the company proposed to transfer Rs 7.00 crores to general reserves during the financial year ended 31 March, 2025.

These balance sheet and reserves references provide context for capital allocation decisions alongside dividend and bonus actions. But the text does not provide a full cash flow bridge for the year in narrative form, beyond a table that lists “Cash From Operating Activities” across years.

Governance and compliance disclosures in early 2026

The dataset includes a 6 Feb entry stating the board authorised two KMPs, Ritesh Shah and Manan Vadhan, to determine materiality and disclose events, dated 06 Feb 2026. There is also an 8 Feb item referencing newspaper publication of unaudited financial results for the quarter ended 31st December, 2025, published in the Financial Express (English) and Mumbai Lakshdeep (as partially shown in the text).

On audit appointments, the statutory auditor Jayantilal Thakkar & Co. is stated to have been appointed to hold office from FY2022-23 to FY2026-27. The company also disclosed appointment and re-appointment items for cost audit, including a remuneration of Rs 1,20,000 plus GST for the cost auditor for FY2025-26, and a separate appointment of a secretarial auditor firm for FY2025-26 to FY2029-30.

Key facts table: dividend, bonus, and market references

Market impact: what the numbers indicate

The immediate market datapoint in the text is the 1.19% decline to Rs 76.64 on 09 Jan 2026, which is presented alongside dividend yield references. The corporate action timetable also frames how market prices are tracked around eligibility dates, with a specific “price on that day” of Rs 207.39 shown for the dividend ex-date entry on 14 Aug 2025.

Financially, the company reported a year-on-year increase in revenue from operations to Rs 661.51 crore in FY2024-25, while profit before tax and profit after tax declined to Rs 61.00 crore and Rs 47.35 crore, respectively. That combination often matters for income-focused investors, because dividend decisions are assessed against both earnings and cash generation, but the provided text does not offer a management commentary on payout sustainability beyond the recommendation and outgo figures.

Analysis: reading the dividend alongside bonus and profits

The dividend recommendation of Rs 1.50 per share for FY2024-25 is repeatedly presented as being on post-bonus share capital, alongside a 1:1 bonus issue. The annual report excerpt also states a higher total dividend outgo (Rs 15.03 crore) than the previous year (Rs 12.53 crore), even as it compares the per-share dividend with a higher prior-year number.

Separately, FY2024-25 profitability declined in the numbers provided, with PAT falling from Rs 60.06 crore to Rs 47.35 crore. That makes the combined set of actions notable because shareholders are looking at a capital return decision and a bonus issue in a year where earnings were lower, even though revenue rose modestly. Governance updates in February 2026, including authorising KMPs for materiality and disclosure, also signal ongoing compliance structuring under listing regulations.

Conclusion

Anuh Pharma’s FY2024-25 disclosures bring together a 1:1 bonus issue, a final dividend of Rs 1.50 per share with a defined ex-date and record date in August 2025, and a year where revenue rose but profits fell. The company also reported total assets of Rs 506.63 crore as of March 31, 2025, and documented several audit and governance appointments.

The next set of milestones referenced in the text is the disclosure flow around unaudited results for the quarter ended December 31, 2025, including the newspaper publication and the 6 Feb authorisation of KMPs for materiality-based disclosures.